Best timing of EGFR re-challenge by monitoring the mutant allele of KRAS/NRAS in liquid biopsy
Not Applicable
- Conditions
- Patients with RAS/BRAF V600E wild-type unresectable advanced or recurrent colorectal cancer who have been treated with anti-EGFR monoclonal antibody
- Registration Number
- JPRN-UMIN000036424
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Not provided
Exclusion Criteria
1)Severe comorbidity. (a)Active multiple cancer (b)Uncontroled central nervous system or leptomeningeal metastasis (c)Mental illness or mental symptoms that would interfere with participation in the study 2)Any patients who are regarded as inadequate for anti-EGFR monoclonal antibody re-challenge by investigators. 3)Intolerant to previous irinotecan therapy. 4)Comorbidity or history of severe pulmonary disease. 5)Men/women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test. 6)Active HCV or HIV infection. 7)Any other patients who are regarded as inadequate for study enrollment by investigators.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method